

### *Overview*

Hot and cold tumor are crucial in assessing the efficacy of existing cancer immunotherapies. A hot tumor is **rich in tumor immune microenvironment (TME)**, PD-L1 overexpression, genomic instability. Example of hot tumors include melanoma and lung cancer. In contrast, non-T- cell inflamed cancers, such as Triple Negative Breast Cancer (TNBC), prostate or pancreas cancers fall into the category of “cold tumors”.

A cold tumor is characterized by 1) low immunogenicity due to lack of neoantigens, and HLA molecules, 2) antigen presentation deficiency attributed to dysfunction of dendritic cells (DCs), 3) impaired T-cell ~~trafficking~~ infiltration, 4) an heterogenous TME determined by a subset of immune cells, such as tumor-associated macrophages (TAMs), tumor-associated neutrophils (TAN), myeloid-derived suppressor cells (MDSCs), and regulatory T cells ( $T_{reg}$ ) [3][4].

Immune checkpoint inhibitors (ICIs) targeting immune checkpoints (such as PD-1, PD-L1, CTL4, TIM-3, and LAG-3) have shown success in improving the survival of cancer patient. ICI-mediated antitumor responses depend on the infiltration of T cells that identify and eliminate cancer cells. Therefore, ICIs are less efficacious in “cold tumors” which are characterized by the lack of T-cell infiltration. Without presentation of neoantigens in cold tumors, the immune checkpoint blockade is attenuated. Additionally, deficiencies in T cell priming mechanisms have been shown to contribute to resistance to immune checkpoint inhibition therapies [5].

### *Specific Aims*

The aims of this project are to analyze the current landscape of strategies designed in “warming up” cold tumors to immune checkpoint inhibitors (ICIs); **to introduce an innovative approach utilizing nanoparticles, viral vectors, or polymeric particles as potential solutions.**


### **Significance**

According to the National Cancer Institute, in 2020, cancer-related healthcare expenses in the U.S. reached \$208.9 billion. Since their peak in 1991, there has been a 33% decline in the rates of most common cancers, including lung, colorectal, breast and prostates, The trend has been attributed to a combination of factors, such as reduced smoking rates, advanced in therapies like ICIs, and the development of improved diagnostic and prognostic biomarkers. Nonetheless, cancer incidence rates have increased in breast, uterine, melanoma and prostate cancers [1].


In last 10 years, the FDA has approved an increasing number of Immune Checkpoint Inhibitors (ICIs) following successful clinical trials. These treatments have significantly enhanced long-term survival rates for metastatic patients and prolong progression-free survival for those in early stages of the disease. Cancer cell can escape detection and destruction by activating different molecules, such as PD1 or CTLA-4 on the surface of



such therapies into effective monotherapies for malignant solid tumors has often been disappointing.

CSF1 inhibition has rarely led to tumor regression. As combinatorial therapy, the outcomes were more encouraging: combining CSF1R inhibitor (PLX3397) with checkpoint inhibitors like PD-1 or CTLA-4 antibodies reduced tumor progression by more than 90%. However, most of the clinical trials were stopped due to observed severe adverse events. Similarly, combining CSF-1/CSF1R inhibitors with conventional treatments like chemotherapy, radiotherapy or targeted therapies have yielded mixed results. 

## Innovation

The Poly (ADP-ribose) polymerase (PARP) family has many crucial functions in cellular processes, including the regulation of transcription, apoptosis, and DNA repair. PARP inhibitors (PARPi) are effective against homologous recombination repair of cancer cells. By blocking PARP, a PARPi-derived drug could trigger DNA damage accumulation, leading to synthetic lethality in cancer cells with defects in DNA repair mechanisms. Additionally, PARPi can upregulate PD-L1 expression and PD-L1 upregulation can contribute to an inflammatory feedback loop that enhances T cell infiltration [2]. 

Research indicates that PARPi can facilitate the recruitment and activation of CD4+ and CD8+ T cells through neoantigen generation and the release of cytokines and chemokines like INF- $\gamma$ , CCL5, and CXCL10 [22, 23].

In cancer therapy, inhibiting CSF-1R has demonstrated to augment the efficacy of PARP inhibitors (PARPi) [23]. This inhibition disrupts the recruitment and activity of tumor-associated macrophages (TAMs), which are often immunosuppressive and promote tumor progression. By targeting CSF-1R, the presence of these TAMs in the tumor microenvironment can be diminished.

Research suggests that the pairing CSF-1R inhibition with PARP inhibitors can lead to synergistic effects, effectively restraining tumor growth and improving treatment outcomes. To the best of our knowledge, there has been no prior exploration into developing such a novel therapy. This approach not only can enhance the anti-tumor immune response but also increases tumor sensitivity to PARP inhibition.

We intend to enhance the therapeutic potential of exosomes derived from iPSC-MSC by utilizing them as carriers for PARPi cargo. These exosomes will be further modified by conjugating them with a CSF-1R inhibitor to target tumor-associated macrophages (TAMs) and cancer cells. To increase specificity and minimize off-target effects, we propose surface modifications of the exosomes derived from MSCs. This modification will involve conjugating the exosome surface with CSF1R, as well as markers specific to TAMs, **such as CD68 or CD163**, and markers specific to various cancer cell types. ~~For instance,~~ epithelial-derived tumors may be targeted using EpCam, breast cancer using HER2, or ovarian cancer using CA125.

## Research Strategy

In this research plan, we outline a comprehensive strategy to develop and characterize exosome-based therapeutics loaded with PARPi cargo and conjugated with CSF-1R inhibitors, specifically designed to target both cancer cells and TAMs within the tumor microenvironment. Our approach integrates multiple facets, including exosome engineering, in vitro efficacy assessment, and in vivo evaluation, with the goal of advancing towards clinical translation.

### *a) Research Outline*

Aim 1: Development and Characterization of Exosome-based Therapeutic for PARPi and CSF-1R Inhibitors.

Sub-aims:

- 1.1. Generate exosomes from iPSC-MSCs and load them with PARPi cargo.
- 1.2. Conjugate the surface of the exosomes with CSF-1R inhibitors and markers specific to TAMs (CD68, CD163) and cancer cells (EpCam, HER2, CA125).

Justification: Efficient loading of PARPi into exosomes is critical for maximizing the therapeutic potential of the drug while minimizing the required dose and associated side effects. This step is fundamental to ensuring that the exosomes can serve as effective drug carriers to the tumor microenvironment.

Benchmarks for Success:

- Successful encapsulation of PARPi into exosomes with over 80% efficiency; demonstration of targeted binding and uptake by TAMs and cancer cells in vitro.
- Verification of targeted conjugation via immunofluorescence staining and Western blotting for TAM and cancer cell markers.

Aim 2: In Vitro Evaluation of Therapeutic Efficacy and Specificity

Sub-aims:

- 2.1. Assess the cytotoxic effects of the engineered exosomes on a panel of cancer cell lines in vitro.
- 2.2. Evaluate the recruitment and activation of immune cells by treated cancer cells, focusing on CD4+ and CD8+ T cells and the impact on TAMs.

Justification:

This aim tests the hypothesis that the engineered exosomes can selectively target cancer cells and TAMs, inducing an anti-tumor immune response while sparing healthy cells.

Benchmarks for Success:

- Demonstrated specificity and cytotoxicity via cell viability assays.
- Increased infiltration and activation of T cells, observed through flow cytometry and cytokine profiling.

Aim 3: In Vivo Efficacy and Safety Evaluation

Sub-aims:

- 3.1. Conduct preclinical trials using relevant animal models to assess the therapeutic efficacy of the exosome-based delivery system.

3.2. Evaluate the safety profile and potential off-target effects of the treatment in animal models.

Justification: This aim addresses the translational potential of the research.

Benchmarks for Success:

- Significant tumor growth inhibition and improved survival rates in treated animals.
- Minimal adverse effects and evidence of targeted delivery to tumor sites.
- No significant toxic effects observed in normal tissue; a detailed mechanistic understanding of how the therapy modulates the tumor microenvironment, supported by changes in immune cell populations and cytokine profiles.

If time allows, we also investigate:

Aim 4: Evaluation of Combination Therapies with Immune Checkpoint Inhibitors to Enhance Antigen-Specific T-cell Activation.

Sub-aims:

4.1. Formulate combination therapy protocols that integrate the use of PD-L1/PD-1 inhibitors with anti-CTLA4 alongside the exosome-based delivery therapeutic agent carrying PARPi and CSF-1R inhibitors.

4.2. Investigate the effects of combination therapies on the priming and activation of antigen-specific CD4+ and CD8+ T-cells in vitro and in vivo.

Justification: The rationale behind this aim is to leverage the complementary mechanisms of action between immune checkpoint inhibitors and the targeted delivery of PARPi and CSF-1R inhibitors via exosomes.

Benchmarks for Success:

- Enhanced activation and proliferation of antigen-specific T-cells, as measured by flow cytometry and ELISPOT assays.
- Synergistic reduction in tumor growth and increased survival in relevant animal models treated with the combination therapy compared to monotherapies.
- Documentation of the immune cell infiltration within the tumor microenvironment through immunohistochemistry.

## **References:**

1. "2024-cancer-facts-and-figures-acf.pdf".
2. X.-F. Yi *et al.*, "Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor," *Biomed. Pharmacother.*, vol. 163, p. 114770, 2023, doi: 10.1016/j.biopha.2023.114770
3. **Turning cold tumors into hot tumors by improving T cell infiltration**  
Yuan-Tong Liu, Zhi-Jun Sun doi: 10.7150/thno.58390
4. **Turning cold tumors hot: from molecular mechanisms to clinical applications**  
Jiahui Zang et al. *Trends in Immunology*
5. **Strategies for Heating Up Cold Tumors to Boost Immunotherapies**  
Danie Zabravsky et al. *Annual Review of Cancer Biology*

a) with chemotherapies to improve patient outcomes.

**6. Hot and cold tumors: Immunological features and the therapeutic strategies**

L Wang, H Geng, Y Liu, L Liu, Y Chen, F Wu, Z Liu- <https://doi.org/10.1002/mco2.343>

7. B. L. Russell, S. A. Sooklal, S. T. Malindisa, L. J. Daka, and M. Ntwasa, “**The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy**” *Front. Oncol.*, vol. 11, p. 641428, 2021, doi: 10.3389/fonc.2021.641428

**8. Combining in site vaccination and immunogenic apoptosis to treat cancer.**

Arman Lamai, Mehdi Shalgolzari – Future Medicine – Immunotherapy – Vol.15, Issue 5

**9. Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy**

Matin Ghasemi et al. *Frontiers in Immunology*

**10. Pouring Petrol on the flames: Using oncolytic virotherapies to enhance tumor immunogenicity.**

Alicia Teijeira Crespo et al. Wiley Library, Immunology

**11. Unlocking the potential of antibody-drug conjugates for cancer therapy**

Joshua Z. Drago et al. doi:10.1038/s41571-021-00470-8.

**12. Tumor Targeting of a Sting Antagonist with an Antibody-Drug Conjugate Elicits Potent Anti-Tumor Immune Responses.**

**13. Antibody-Drug Conjugates: A Review of Approved Drugs and Their Clinical Level of Evidence**

Review by Pooja Gogi et al. *Cancers*

**14. The Evolution of Antibody-Drug Conjugates: A Positive Inflexion Point**

Anthony W. Tolcher - ASCO Educational Book

**15. Igniting Hope for Tumor Immunotherapy: Promoting the “Hot and Cold” Tumor Transition**

Chen Wei et al., DOI: 10.1177/11795549221120708

Sage Journal: Clinical Medicine Insights: Oncology Volume 16.

**16. Advancing cellular immunotherapy with macrophages**

Alok K. Mishra et al. DOI: <https://doi.org/10.1016/j.lfs.2023.121857>

**17. Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy**

Hongyu Zheng et al. *Cell Death Discovery* (2023(9: 65) Nature

Doi: <https://doi.org/10.1038/s41420-023-01356-7>

**18. CSF1R inhibitors are emerging immunotherapeutic drugs for cancer treatment.**

Jiachen Wen et al., DOI: 10.1016/j.ejmech.2022.114884

Elsevier - European Journal of Medicinal Chemistry

**19. Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma**

Iva Truxova et al., DOI: 10.1136/jitc-2022-005968

Journal for Immunotherapy 2023

**20. Sophisticated genetically engineered macrophages, CAR-Macs, in hitting the bull's eye for solid cancer immunotherapy.**

Nese Unver, DOI: <https://doi.org/10.1007/s10238-023-01106-0>

Clinical and Experimental Medicine 2023

**21. Engineering extracellular vesicles derived from macrophages for tumor therapy.**

Ying Yan et al., DOI: 10.1039/D2MA00961G

Royal Society of Chemistry

**22. Recent advances in macrophage-derived exosomes as delivery vehicles**

Shumin Wang et al. DOI: <https://doi.org/10.26599/NTM.2022.9130013>

**23. Therapeutic Targeting of DNA Damage Repair in the Era of Precision Oncology and Immune Checkpoint Inhibitors**

Curis Clark et al., DOI: <https://doi.org/10.36401/JIPO-22-15>

**24. Dual antitumor immunomodulatory effects of PARP inhibitor on the tumor microenvironment: A counterbalance between anti-tumor and pro-tumor**

Xiao-Fang Yi et al., DOI: 10.1016/j.biopha.2023.114770

ELSEVIER - Biomedicine & Pharmacotherapy 163

**25. The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy.**

Havel JJ, Chowell D, Chan TA (2019), Nat Rev Cancer 19(3):133–

150. <https://doi.org/10.1038/s41568-019-0116-x>

**26. Beyond DNA repair, the immunological role of PARP-1 and its siblings.**

Rosado MM, Bennici E, Novelli F, Pioli C (2013) Immunology 139(4):428–

437. <https://doi.org/10.1111/imm.12099>